医药板块大爆发Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_城市资讯网
l-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's p lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the 当前文章：http://a73d.kuailianwas.com.cn/hg1dr/3vp.docx 发布时间：12:22:32 |
